EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--June 7, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will make a presentation to the investment community at the Goldman Sachs 26th Annual Global Healthcare Conference, held June 13-16, in Dana Point, California. The conference will feature presentations by more than 120 companies.
Bruce Barclay, President and Chief Operating Officer and Phil Ankeny, Chief Financial Officer and Vice President, Business Development are scheduled to present an overview of the company and its growth strategies on Tuesday, June 14, at 12:50 p.m. (ET).
Interested parties may access a live webcast of the presentation by logging on to the Investors section of the SurModics website at www.surmodics.com. Investors are advised to visit the site at least 10 minutes before the scheduled presentation to register, download and install any necessary multimedia streaming software. The software plug-ins required for the live event can be either RealPlayer or Windows Media Player. The audio file of this webcast will be archived and available on the Company's site for 30 days.
About SurModics, Inc.
SurModics, Inc. is a leading provider of surface modification technologies, in the areas of biocompatibility, site-specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. A significant portion of SurModics' revenue is generated by royalties from the sale of commercial products resulting from its corporate relationships. Recent collaborative efforts include the implementation of the SurModics' Bravo(TM) drug delivery polymer matrix as a key component in the first-to-market drug-eluting coronary stent. SurModics is headquartered in Minneapolis, MN and more information about the company can be found at www.surmodics.com. The content of SurModics' web site is not part of this release or part of any filings the company makes with the SEC.
CONTACT: SurModics, Inc.
Phil Ankeny, 952-829-2700
SOURCE: SurModics, Inc.